Department of Orthopedic surgery, Second Hospital of Lanzhou University, Gansu Province 730000, PR China.
J Med Microbiol. 2022 Nov;71(11). doi: 10.1099/jmm.0.001622.
Bushen Zhuangjin Decoction (BZD), a well-known formulation in Traditional Chinese Medicine, has been widely used for the treatment of osteoarthritis (OA). Due to the poor intrinsic repair capacity of chondrocytes, promoting the proliferation of chondrocytes is an efficient treatment to delay the progression of cartilage degradation. Therefore, to explore the regulatory mechanism of Bushen Zhuangjin Decoction in chondrocytes will contribute to the repair of chondrocyte injury in OA, and may serve as a potential therapy for OA diseases. To investigate the expression and distribution of SOX9 mediated by serum containing Bushen Zhuangjin Decoction (BZD) and its therapeutic effect on chondrocyte injury in rats.. The subcultured second-generation rat chondrocytes were randomly divided into four groups, and they were intervened with medium containing different serums, including: blank serum group, low-concentration BZD group, medium-concentration BZD group, and high-concentration BZD group. The viability, proliferation and apoptosis of chondrocytes were detected by MTT assay and flow cytometry. The gene and protein levels of SOX9, aggrecan and type II collagen genes were analysed by qRT-PCR and Western blot analysis. Immunofluorescence staining was used to analyse the expression and distribution of SOX9. Inflammatory factors in different culture mediums of chondrocytes were detected by ELISA. Compared with the control group, the activity of chondrocytes in the BZD drug-containing serum group was significantly enhanced, and the degree of apoptosis was significantly decreased. The gene and protein levels of SOX9, proteoglycan aggrecan and collagen II in chondrocytes increased significantly. The inflammatory factors in the culture medium also decreased significantly. And in the above experiments, the medium concentration group BZD drug-containing serum had the best effect. Our research results show that BZD medicated serum can up-regulate the expression of SOX9, reduce the release of inflammatory factors, and promote changes in the phenotype of chondrocytes, which protects chondrocytes from damage.
补肾壮筋汤(BZD)是一种中药名方,广泛用于治疗骨关节炎(OA)。由于软骨细胞内在修复能力差,促进软骨细胞增殖是延缓软骨降解进展的有效治疗方法。因此,探索补肾壮筋汤对软骨细胞的调控机制将有助于修复 OA 中的软骨细胞损伤,可能成为 OA 疾病的潜在治疗方法。为了研究补肾壮筋汤含药血清对 SOX9 的表达和分布的调节作用及其对大鼠软骨细胞损伤的治疗作用。将第二代传代大鼠软骨细胞随机分为四组,分别用含有不同血清的培养基干预,包括:空白血清组、低浓度 BZD 组、中浓度 BZD 组和高浓度 BZD 组。通过 MTT 法和流式细胞术检测软骨细胞的活力、增殖和凋亡。采用 qRT-PCR 和 Western blot 分析 SOX9、聚集蛋白聚糖和 II 型胶原基因的基因和蛋白水平。免疫荧光染色分析 SOX9 的表达和分布。通过 ELISA 检测不同软骨细胞培养基中的炎症因子。与对照组相比,BZD 含药血清组的软骨细胞活性明显增强,凋亡程度明显降低。软骨细胞中 SOX9、蛋白聚糖聚集蛋白聚糖和 II 型胶原的基因和蛋白水平明显增加。培养基中的炎症因子也明显下降。在上述实验中,BZD 药物浓度组含药血清效果最好。我们的研究结果表明,BZD 含药血清能上调 SOX9 的表达,减少炎症因子的释放,促进软骨细胞表型的改变,从而保护软骨细胞免受损伤。